TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...

Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant ...

Next year is bringing many changes to the regulatory landscape for skilled nursing. With new payment rules, coding changes ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated ...

“For many years, the standard of care for ASHL was based on the RATHL trial, where newly diagnosed patients were given two cycles of ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] and ...

Market forecasters project the CAR-T cell therapy market will surge from $3.87 billion in 2024 to $13.25 billion by 2030, driven by unprecedented efficacy in relapsed and refractory patient ...

Beyond blood cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and ...

Myelodysplastic syndromes (MDS) are a group of related conditions that interfere with the body’s ability to make healthy blood cells. They are a type of blood cancer. In the early stages of ...

FRONTLINE Editor-in-Chief and Executive Producer Raney Aronson-Rath sits down with journalists and filmmakers for probing conversations about the investigative journalism that drives each FRONTLINE ...

TURKU, FINLAND / ACCESS Newswire / December 17, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers ...